目的 探讨Roux-en-Y胃转流术对代谢综合征大鼠肥胖相关指标、糖脂代谢指标、器官脂肪组织过氧化物酶体增长因子活化受体γ(PPAR-γ)蛋白表达的影响.方法 40只健康雄性7～8周龄SD大鼠,适应性喂养l周后,选取30只,予高糖高脂高盐饲料配合20％蔗糖水喂养12周,筛选出24只符合标准的代谢综合征模型大鼠,按完全随机区段分组法分为假手术组(11只)和手术组(13只).假手术组行胃窦十二指肠离断原位吻合术,手术组行Roux-en-Y胃转流术.其余10只健康SD大鼠予标准饮食喂养设为正常组.术后5周处死大鼠,立即取肠系膜、双肾周及双侧附睾旁脂肪组织,采用Western blot法检测大鼠器官脂肪组织PPAR-γ蛋白含量.观察指标包括:(1)肥胖相关指标:术前及术后5周进食量、体质量、腹围、Lee's指数,术后5周器官脂肪质量、器官脂肪系数.(2)糖脂代谢指标:术前及术后5周空腹血糖、血清胰岛素、稳态胰岛素评价指数(HOMA-IR)、TC、TG、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、血清游离脂肪酸.(3)术后5周器官脂肪组织PPAR-γ蛋白含量.正态分布的计量资料以-x±s表示,多组间比较采用方差分析,两组间比较采用LSD-t检验,重复测量数据采用重复测量方差分析.结果 手术组大鼠术后1周死亡3只,死亡率为3/13;其余各组无大鼠死亡.正常组大鼠进食量、体质量、腹围、Lee's指数术前分别为(26.9±1.5)g、(499 ±46)g、(18.2 ±0.4)cm、309±9,术后5周分别为(27.7±2.1)g、(547 ±43)g、(18.6 ±0.5)cm、312±8;假手术组大鼠上述指标术前分别为(26.1±1.8)g、(584±42)g、(19.3±0.6)cm、(317±13),术后5周分别为(28.8±1.7)g、(677 ±39)g、(20.6 ±0.7)cm、334±11;手术组大鼠上述指标术前分别为(25.9±2.1)g、(579 ±47)g、(19.4±0.5)cm、311 ±5,术后5周分别为(17.5±0.8)g、(470±40)g、(18.1 ±0.4)cm、302 ±4;上述指标术前3组比较,差异均无统计学意义(F =0.821,0.784,0.813,0.642,P＞0.05);上述指标术前至术后5周变化趋势,3组比较,差异均有统计学意义(F=4.650,3.852,4.362,4.042,P＜0.05).正常组大鼠术后5周器官脂肪质量、器官脂肪系数分别为(34±6)g、6.2％±0.5％,假手术组分别为(55 ±6)g、8.2％±0.6％,手术组分别为(28±6)g、6.1％±0.5％;3组大鼠上述2个指标比较,差异均有统计学意义(F=16.750,14.686,P＜0.05).术后5周器官脂肪质量正常组与假手术组比较,差异有统计学意义(t=4.287,P＜0.05);正常组与手术组比较,差异无统计学意义(t=1.225,P＞0.05);假手术组与手术组比较,差异有统计学意义(t=5.511,P＜0.05).术后5周器官脂肪系数正常组与假手术组比较,差异有统计学意义(t=4.435,P＜0.05);正常组与手术组比较,差异无统计学意义(t=0.245,P＞0.05);假手术组与手术组比较,差异有统计学意义(t=4.657,P＜0.05).正常组大鼠空腹血糖、血清胰岛素、HOMA-IR、TC、TG、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、血清游离脂肪酸术前分别为(4.3±0.9)mmol/L、(15.1 ±4.9)μmol/L、2.19±1.43、(1.12 ±0.13) mmol/L、(1.3±0.5)mmol/L、(1.32±0.19)mmol/L、(0.9±0.4)mmol/L、(131±17) mmol/L,术后5周分别为(4.3±1.2) mmol/L、(14.8±5.3)μmol/L、2.29±1.37、(1.07±0.16) mmol/L、(1.2±0.7)mmol/L、(1.28±0.22) mmol/L、(0.8±0.5)mmol/L、(134±19) mmol/L;假手术组大鼠上述指标术前分别为(6.1±0.7)mmol/L、(30.1±1.8) μmol/L、7.86±1.56、(3.32±0.14) mmol/L、(2.5±0.6)mmol/L、(0.81±0.21) mmol/L、(2.8±0.7) mmol/L、(178±18) mmol/L,术后5周分别为(6.1 ±0.7) mmol/L、(31.6 ±2.1)μmol/L、8.50±1.66、(3.43 ±0.12) mmol/L、(2.7±0.5)mmol/L、(0.84 ±0.24) mmol/L、(3.1±0.5)mmol/L、(182±19) mmol/L;手术组大鼠上述指标术前分别为(6.2±0.6) mmol/L、(29.6±2.7)μmol/L、7.43±1.03、(3.36±0.15) mmol/L、(2.6±0.5)mmol/L、(0.79 ±0.17) mmol/L、(2.9 ±0.6)mmol/L、(180±17) mmol/L,术后5周分别为(4.5±0.8)mmol/L、(19.5±1.0) μmol/L、5.17 ±0.25、(1.46±0.08) mmol/L、(1.5 ±0.4)mmol/L、(1.09 ±0.18) mmol/L、(1.2 ±0.3)mmol/L、(146±16)mmol/L;上述指标术前3组比较,差异均无统计学意义(F =0.625,0.746,0.813,0.649,0.754,0.823,0.587,0.648,P＞0.05);术前至术后5周变化趋势,3组比较,差异均有统计学意义(F =4.714,14.921,18.971,20.544,5.731,6.143,10.276,6.607,P＜0.05).正常组、假手术组、手术组大鼠术后5周器官脂肪组织PPAR-γ蛋白含量分别为0.79±0.26、0.22±0.17、1.18±0.37,3组比较,差异有统计学意义(F=8.988,P＜0.05);正常组与假手术组比较,差异有统计学意义(t=3.178,P＜0.05);正常组与手术组比较,差异无统计学意义(t=1.494,P＞0.05);假手术组与手术组比较,差异有统计学意义(t =4.084,P＜0.05).结论 Roux-en-Y胃转流术可减少代谢综合征大鼠器官脂肪堆积,改善糖脂代谢和胰岛素抵抗,上调器官脂肪组织PPAR-γ表达.
目的 探討Roux-en-Y胃轉流術對代謝綜閤徵大鼠肥胖相關指標、糖脂代謝指標、器官脂肪組織過氧化物酶體增長因子活化受體γ(PPAR-γ)蛋白錶達的影響.方法 40隻健康雄性7～8週齡SD大鼠,適應性餵養l週後,選取30隻,予高糖高脂高鹽飼料配閤20％蔗糖水餵養12週,篩選齣24隻符閤標準的代謝綜閤徵模型大鼠,按完全隨機區段分組法分為假手術組(11隻)和手術組(13隻).假手術組行胃竇十二指腸離斷原位吻閤術,手術組行Roux-en-Y胃轉流術.其餘10隻健康SD大鼠予標準飲食餵養設為正常組.術後5週處死大鼠,立即取腸繫膜、雙腎週及雙側附睪徬脂肪組織,採用Western blot法檢測大鼠器官脂肪組織PPAR-γ蛋白含量.觀察指標包括:(1)肥胖相關指標:術前及術後5週進食量、體質量、腹圍、Lee's指數,術後5週器官脂肪質量、器官脂肪繫數.(2)糖脂代謝指標:術前及術後5週空腹血糖、血清胰島素、穩態胰島素評價指數(HOMA-IR)、TC、TG、高密度脂蛋白膽固醇、低密度脂蛋白膽固醇、血清遊離脂肪痠.(3)術後5週器官脂肪組織PPAR-γ蛋白含量.正態分佈的計量資料以-x±s錶示,多組間比較採用方差分析,兩組間比較採用LSD-t檢驗,重複測量數據採用重複測量方差分析.結果 手術組大鼠術後1週死亡3隻,死亡率為3/13;其餘各組無大鼠死亡.正常組大鼠進食量、體質量、腹圍、Lee's指數術前分彆為(26.9±1.5)g、(499 ±46)g、(18.2 ±0.4)cm、309±9,術後5週分彆為(27.7±2.1)g、(547 ±43)g、(18.6 ±0.5)cm、312±8;假手術組大鼠上述指標術前分彆為(26.1±1.8)g、(584±42)g、(19.3±0.6)cm、(317±13),術後5週分彆為(28.8±1.7)g、(677 ±39)g、(20.6 ±0.7)cm、334±11;手術組大鼠上述指標術前分彆為(25.9±2.1)g、(579 ±47)g、(19.4±0.5)cm、311 ±5,術後5週分彆為(17.5±0.8)g、(470±40)g、(18.1 ±0.4)cm、302 ±4;上述指標術前3組比較,差異均無統計學意義(F =0.821,0.784,0.813,0.642,P＞0.05);上述指標術前至術後5週變化趨勢,3組比較,差異均有統計學意義(F=4.650,3.852,4.362,4.042,P＜0.05).正常組大鼠術後5週器官脂肪質量、器官脂肪繫數分彆為(34±6)g、6.2％±0.5％,假手術組分彆為(55 ±6)g、8.2％±0.6％,手術組分彆為(28±6)g、6.1％±0.5％;3組大鼠上述2箇指標比較,差異均有統計學意義(F=16.750,14.686,P＜0.05).術後5週器官脂肪質量正常組與假手術組比較,差異有統計學意義(t=4.287,P＜0.05);正常組與手術組比較,差異無統計學意義(t=1.225,P＞0.05);假手術組與手術組比較,差異有統計學意義(t=5.511,P＜0.05).術後5週器官脂肪繫數正常組與假手術組比較,差異有統計學意義(t=4.435,P＜0.05);正常組與手術組比較,差異無統計學意義(t=0.245,P＞0.05);假手術組與手術組比較,差異有統計學意義(t=4.657,P＜0.05).正常組大鼠空腹血糖、血清胰島素、HOMA-IR、TC、TG、高密度脂蛋白膽固醇、低密度脂蛋白膽固醇、血清遊離脂肪痠術前分彆為(4.3±0.9)mmol/L、(15.1 ±4.9)μmol/L、2.19±1.43、(1.12 ±0.13) mmol/L、(1.3±0.5)mmol/L、(1.32±0.19)mmol/L、(0.9±0.4)mmol/L、(131±17) mmol/L,術後5週分彆為(4.3±1.2) mmol/L、(14.8±5.3)μmol/L、2.29±1.37、(1.07±0.16) mmol/L、(1.2±0.7)mmol/L、(1.28±0.22) mmol/L、(0.8±0.5)mmol/L、(134±19) mmol/L;假手術組大鼠上述指標術前分彆為(6.1±0.7)mmol/L、(30.1±1.8) μmol/L、7.86±1.56、(3.32±0.14) mmol/L、(2.5±0.6)mmol/L、(0.81±0.21) mmol/L、(2.8±0.7) mmol/L、(178±18) mmol/L,術後5週分彆為(6.1 ±0.7) mmol/L、(31.6 ±2.1)μmol/L、8.50±1.66、(3.43 ±0.12) mmol/L、(2.7±0.5)mmol/L、(0.84 ±0.24) mmol/L、(3.1±0.5)mmol/L、(182±19) mmol/L;手術組大鼠上述指標術前分彆為(6.2±0.6) mmol/L、(29.6±2.7)μmol/L、7.43±1.03、(3.36±0.15) mmol/L、(2.6±0.5)mmol/L、(0.79 ±0.17) mmol/L、(2.9 ±0.6)mmol/L、(180±17) mmol/L,術後5週分彆為(4.5±0.8)mmol/L、(19.5±1.0) μmol/L、5.17 ±0.25、(1.46±0.08) mmol/L、(1.5 ±0.4)mmol/L、(1.09 ±0.18) mmol/L、(1.2 ±0.3)mmol/L、(146±16)mmol/L;上述指標術前3組比較,差異均無統計學意義(F =0.625,0.746,0.813,0.649,0.754,0.823,0.587,0.648,P＞0.05);術前至術後5週變化趨勢,3組比較,差異均有統計學意義(F =4.714,14.921,18.971,20.544,5.731,6.143,10.276,6.607,P＜0.05).正常組、假手術組、手術組大鼠術後5週器官脂肪組織PPAR-γ蛋白含量分彆為0.79±0.26、0.22±0.17、1.18±0.37,3組比較,差異有統計學意義(F=8.988,P＜0.05);正常組與假手術組比較,差異有統計學意義(t=3.178,P＜0.05);正常組與手術組比較,差異無統計學意義(t=1.494,P＞0.05);假手術組與手術組比較,差異有統計學意義(t =4.084,P＜0.05).結論 Roux-en-Y胃轉流術可減少代謝綜閤徵大鼠器官脂肪堆積,改善糖脂代謝和胰島素牴抗,上調器官脂肪組織PPAR-γ錶達.
목적 탐토Roux-en-Y위전류술대대사종합정대서비반상관지표、당지대사지표、기관지방조직과양화물매체증장인자활화수체γ(PPAR-γ)단백표체적영향.방법 40지건강웅성7～8주령SD대서,괄응성위양l주후,선취30지,여고당고지고염사료배합20％자당수위양12주,사선출24지부합표준적대사종합정모형대서,안완전수궤구단분조법분위가수술조(11지)화수술조(13지).가수술조행위두십이지장리단원위문합술,수술조행Roux-en-Y위전류술.기여10지건강SD대서여표준음식위양설위정상조.술후5주처사대서,립즉취장계막、쌍신주급쌍측부고방지방조직,채용Western blot법검측대서기관지방조직PPAR-γ단백함량.관찰지표포괄:(1)비반상관지표:술전급술후5주진식량、체질량、복위、Lee's지수,술후5주기관지방질량、기관지방계수.(2)당지대사지표:술전급술후5주공복혈당、혈청이도소、은태이도소평개지수(HOMA-IR)、TC、TG、고밀도지단백담고순、저밀도지단백담고순、혈청유리지방산.(3)술후5주기관지방조직PPAR-γ단백함량.정태분포적계량자료이-x±s표시,다조간비교채용방차분석,량조간비교채용LSD-t검험,중복측량수거채용중복측량방차분석.결과 수술조대서술후1주사망3지,사망솔위3/13;기여각조무대서사망.정상조대서진식량、체질량、복위、Lee's지수술전분별위(26.9±1.5)g、(499 ±46)g、(18.2 ±0.4)cm、309±9,술후5주분별위(27.7±2.1)g、(547 ±43)g、(18.6 ±0.5)cm、312±8;가수술조대서상술지표술전분별위(26.1±1.8)g、(584±42)g、(19.3±0.6)cm、(317±13),술후5주분별위(28.8±1.7)g、(677 ±39)g、(20.6 ±0.7)cm、334±11;수술조대서상술지표술전분별위(25.9±2.1)g、(579 ±47)g、(19.4±0.5)cm、311 ±5,술후5주분별위(17.5±0.8)g、(470±40)g、(18.1 ±0.4)cm、302 ±4;상술지표술전3조비교,차이균무통계학의의(F =0.821,0.784,0.813,0.642,P＞0.05);상술지표술전지술후5주변화추세,3조비교,차이균유통계학의의(F=4.650,3.852,4.362,4.042,P＜0.05).정상조대서술후5주기관지방질량、기관지방계수분별위(34±6)g、6.2％±0.5％,가수술조분별위(55 ±6)g、8.2％±0.6％,수술조분별위(28±6)g、6.1％±0.5％;3조대서상술2개지표비교,차이균유통계학의의(F=16.750,14.686,P＜0.05).술후5주기관지방질량정상조여가수술조비교,차이유통계학의의(t=4.287,P＜0.05);정상조여수술조비교,차이무통계학의의(t=1.225,P＞0.05);가수술조여수술조비교,차이유통계학의의(t=5.511,P＜0.05).술후5주기관지방계수정상조여가수술조비교,차이유통계학의의(t=4.435,P＜0.05);정상조여수술조비교,차이무통계학의의(t=0.245,P＞0.05);가수술조여수술조비교,차이유통계학의의(t=4.657,P＜0.05).정상조대서공복혈당、혈청이도소、HOMA-IR、TC、TG、고밀도지단백담고순、저밀도지단백담고순、혈청유리지방산술전분별위(4.3±0.9)mmol/L、(15.1 ±4.9)μmol/L、2.19±1.43、(1.12 ±0.13) mmol/L、(1.3±0.5)mmol/L、(1.32±0.19)mmol/L、(0.9±0.4)mmol/L、(131±17) mmol/L,술후5주분별위(4.3±1.2) mmol/L、(14.8±5.3)μmol/L、2.29±1.37、(1.07±0.16) mmol/L、(1.2±0.7)mmol/L、(1.28±0.22) mmol/L、(0.8±0.5)mmol/L、(134±19) mmol/L;가수술조대서상술지표술전분별위(6.1±0.7)mmol/L、(30.1±1.8) μmol/L、7.86±1.56、(3.32±0.14) mmol/L、(2.5±0.6)mmol/L、(0.81±0.21) mmol/L、(2.8±0.7) mmol/L、(178±18) mmol/L,술후5주분별위(6.1 ±0.7) mmol/L、(31.6 ±2.1)μmol/L、8.50±1.66、(3.43 ±0.12) mmol/L、(2.7±0.5)mmol/L、(0.84 ±0.24) mmol/L、(3.1±0.5)mmol/L、(182±19) mmol/L;수술조대서상술지표술전분별위(6.2±0.6) mmol/L、(29.6±2.7)μmol/L、7.43±1.03、(3.36±0.15) mmol/L、(2.6±0.5)mmol/L、(0.79 ±0.17) mmol/L、(2.9 ±0.6)mmol/L、(180±17) mmol/L,술후5주분별위(4.5±0.8)mmol/L、(19.5±1.0) μmol/L、5.17 ±0.25、(1.46±0.08) mmol/L、(1.5 ±0.4)mmol/L、(1.09 ±0.18) mmol/L、(1.2 ±0.3)mmol/L、(146±16)mmol/L;상술지표술전3조비교,차이균무통계학의의(F =0.625,0.746,0.813,0.649,0.754,0.823,0.587,0.648,P＞0.05);술전지술후5주변화추세,3조비교,차이균유통계학의의(F =4.714,14.921,18.971,20.544,5.731,6.143,10.276,6.607,P＜0.05).정상조、가수술조、수술조대서술후5주기관지방조직PPAR-γ단백함량분별위0.79±0.26、0.22±0.17、1.18±0.37,3조비교,차이유통계학의의(F=8.988,P＜0.05);정상조여가수술조비교,차이유통계학의의(t=3.178,P＜0.05);정상조여수술조비교,차이무통계학의의(t=1.494,P＞0.05);가수술조여수술조비교,차이유통계학의의(t =4.084,P＜0.05).결론 Roux-en-Y위전류술가감소대사종합정대서기관지방퇴적,개선당지대사화이도소저항,상조기관지방조직PPAR-γ표체.
Objective To investigate the effects of Roux-en-Y gastric bypass surgery on the obesity-related indexes, glycolipid metabolism indexes and expression of peroxisome proliferator-activatived receptor-γ (PPAR-γ) protein in visceral adipose tissues of rats with metabolic syndrome.Methods After 40 Sprague Dawley (SD) male rats with the age of 7-8 weeks were adaptively fed for 1 week, 30 rats were selected randomly and were fed with high-fat, high glucose and high salt diet combined with sucrose water for 12 weeks, and then 24 rats with metabolic syndrome were screened for eligibility and were allocated into the model group (n =11) and the operation group (n =13) based on the randomized complete block design.Rats of the model group and operation group received transection and reanastomosis of the gastrointestinal tract and Roux-en-Y gastric bypass surgery, respectively.Other 10 rats receiving normal feeding were divided into the control group.After executing rats at postoperative week 5, the levels of PPAR-γprotein in visceral adipose tissues around mesentery, double kidneys and bilateral epididymis were detected by the Western blot.Observation indexes: (1) obesity-related indexes included food intake before operation and at postoperative week 5, body weight, abdominal circumference, Lee's index, visceral adipose weight at postoperative week 5 and visceral adipose coefficient.(2) Glycolipid metabolism indexes included fasting plasma glucose before operation and at postoperative week 5, fasting serum insulin,homeostasis model assessment-insulin resistance (HOMA-IR), total cholesterol (TC), triglyceride (TG), high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C) and free fatty acid (FFA).(3) Level of PPAR-γprotein in visceral adipose tissues at postoperative week 5.Measurement data with normal distribution were presented as-x ± s.Comparison among groups was analyzed using the ANOVA, and comparison between groups was analyzed using the LSD-t test.Repeated measures data were analyzed by the repeated measures ANOVA.Results Three rats in the operation group were dead at postoperative week 1 with a mortality of 3/13 and no death was occurred in other groups.The consumption of food, body weight, abdominal circumference, Lee's index before operation and at postoperative week 5 were (26.9 ± 1.5) g, (499 ± 46) g, (18.2 ± 0.4) cm, 309 ± 9 and (27.7 ± 2.1) g, (547 ± 43) g, (18.6 ± 0.5) cm, 312 ± 8 in the control group, (26.1 ±l.8)g, (584 ±42)g, (19.3 ±0.6)cm, 317 ±13 and (28.8 ± 1.7)g, (677 ±39)g, (20.6 ±0.7)cm, 334 ± 11 in the model group, (25.9 ± 2.1) g, (579 ± 47) g, (19.4 ± 0.5) cm, 311 ± 5 and (17.5 ± 0.8) g, (470 ±40)g, (18.1 ± 0.4)cm, 302 ± 4 in the operation group, respectively, with no significant difference in the above indexes before operation among the 3 groups (F =0.821, 0.784, 0.813, 0.642, P ＞ 0.05) , and with significant differences in the changing trends of above indexes of 3 groups between before operation and postoperative week 5 (F =4.650, 3.852, 4.362, 4.042, P ＜ 0.05).The visceral adipose weight at postoperative week 5 and visceral adipose coefficient were (34 ± 6) g and 6.2％ ± 0.5％ in the control group, (55 ±6)g and 8.2％ ±0.6％ in the model group and (28 ±6) g and 6.1％ ±0.5％ in the operation group, respectively, with significant differences in the above indexes (F =16.750, 14.686, P ＜ 0.05).There were significant differences in the visceral adipose weight at postoperative week 5 not only between control group and model group but also between model group and operation group (t =4.287, 5.511, P ＜ 0.05), and no significant difference between control group and operation group (t =1.225, P ＞ 0.05).There were significant differences in the visceral adipose coefficient at postoperative week 5 not only between control group and model group but also between model group and operation group (t =4.435, 4.657, P ＜ 0.05), and no significant difference between control group and operation group (t =0.245, P ＞ 0.05).The fasting plasma glucose, fasting serum insulin, HOMA-IR, TC, TG, HDL-C, LDL-C and FFA before operation and at postoperative week 5 were (4.3 ± 0.9) mmol/L, (15.1 ± 4.9) μmol/L, 2.19 ± 1.43, (1.12 ± 0.13) mmol/L, (1.3 ± 0.5) mmol/L, (1.32 ± 0.19) mmol/L, (0.9 ± 0.4) mmol/L, (131 ± 17) mmol/L and (4.3 ± 1.2) mmol/L, (14.8 ± 5.3) μmol/L, 2.29 ± 1.37, (1.07 ± 0.16) mmol/L, (1.2 ± 0.7) mmol/L, (1.28 ± 0.22) mmol/L, (0.8 ± 0.5) mmol/L and (134 ± 19) mmol/L in the control group, (6.1 ± 0.7) mmol/L, (30.1 ± 1.8) μmol/L, 7.86 ± 1.56, (3.32 ± 0.14)mmol/L, (2.5 ±0.6)mmol/L, (0.81 ±0.21) mmol/L, (2.8 ±0.7) mmol/L, (178 ± 18) mmol/L and 6.1±0.7)mmol/L, (31.6 ±2.1)μmol/L, 8.50±1.66, (3.43 ±0.12)mmol/L, (2.7 ±0.5)mmol/L, 0.84 ± 0.24) mmol/L, (3.l ± 0.5) mmol/L, (182 ± 19) mmol/L in the model group, (6.2 ± 0.6) mmol/L, 29.6 ± 2.7) μmol/L, 7.43 ± 1.03, (3.36 ± 0.15) mmol/L, (2.6 ± 0.5) mmol/L, (0.79 ± 0.17) mmol/L, 2.9 ± 0.6) mmol/L, (180 ± 17) mmol/L and (4.5 ± 0.8) mmol/L, (19.5 ± 1.0) μmol/L, 5.17 ± 0.25, 1.46 ±0.08)mmol/L, (1.5 ±0.4)mmol./L, (1.09 ±0.18) mmol/L, (1.2 ±0.3)mmol/L, (146 ± 16)mmol/L in the operation group, respectively.There was no significant difference in the above indexes before operation among the 3 groups (F =0.625,0.746, 0.813, 0.649, 0.754, 0.823, 0.587, 0.648, P ＞ 0.05).There were significant differences in the changing trends from before operation to postoperative week 5 among the 3 groups (F=4.714, 14.921, 18.971, 20.544, 5.731,6.143, 10.276, 6.607, P＜0.05).Level of PPAR-γ protein in visceral adipose tissues at postoperative week 5 in the control group, model group and operation group were 0.79 ± 0.26, 0.22 ± 0.17, 1.18 ± 0.37, respectively, showing a significant difference among the 3 groups (F =8.988, P ＜ 0.05).There were significant differences in the level of PPAR-γ protein not only between control group and model group but also between model group and operation group (t =3.178, 4.084, P ＜0.05), and no significant difference between control group and operation group (t =1.494, P ＞ 0.05).Conclusion Roux-en-Y gastric bypass surgery can reduce the visceral fat accumulation of rats with metabolic syndrome, improve metabolism of glucose and lipid and increase expression of PPAR-γ protein in visceral adipose tissue.
